PPT-the costs of cancer: addressing patient costs

2018 Illinois cancer symposium Christine Callahan PhD LCSWC Research Assistant Professor University of Maryland School of Social WorkFinancial Social Work Initiative FSWI Some background. Trends, Transitions, Technology, and Talent. Ricardo Martinez, MD, FACEP. Chief Medical Officer. North Highland Company, . North Highland Worldwide. It Starts…. Care given at home. People paid out of their pockets directly. The future of The Bahamas without energy reform measures . Bahamas Chamber of Commerce and Employers’ Confederation. Nicola . Virgill. . Rolle. , PhD. Director. National Development and Planning. The Energy Situation Today. Award and Assessment of Costs. Hong . Kong 2017 . Mary Thomson. . Chartered Arbitrator, Barrister, Mediator & Adjudicator. Vice Chair, CIArb EAB . . 1. Award . and Assessment of Costs. Introduction. eventsof. . nivolumab. and . docetaxel. in the . CheckMate. 017 and . CheckMate. 057 phase III NSCLC trials. . Kartik. . Venkatachalam. Intervista a Cesare . Gridelli. Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both trials, more TRAEs were observed with doc than with nivo (Table), and the cost of managing TRAEs was 15.8 and 10.7 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials, respectively. Patients in the doc arm incurred an additional $6,585 and $5,422 per patient in managing AEs compared with patients in the nivo arm in the above two trials, respectively. The total estimated costs of managing TRAEs during these trials are presented in the Table. Conclusions: Large estimated differences in costs were observed in managing TRAEs, favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials. The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population.. 1. Michael L. Marlow, Professor of Economics, Cal Poly - San Luis Obispo. Disclosures. : Presentation draws partially on work based on funded studies.. Affiliated Scholar of the Center for the Study of Economic Liberty at Arizona State University, 2016- . Grant to write . . Yvonne . Jonk, PhD. 1. ; Michael . Niedzielski. , PhD. 2. ; . Gary . Wingrove. , . FACPE. 3,4. ; . Nikiah. . Nudell. , MS, . NRP. 3. ; Lindsey . Narloch. , MS. 5. ;Tom . Nehring. , . BS. 5,6. Now. What is Med. Now. ?. On Demand Care. Specialty Care. 24/7. Save time & Money. Easy Access. Opening up access. Keeping . care local. On Demand Primary Care Symptoms. Allergies. Back Pain. Bites & stings. Research co-funded by our partner the RBS GroupExecutive summaryDay-to-day livingClothing equipment and modi31cationsWider contextReferences Cancer146s hidden price tag revealing the costs behind the 2020 Edition Cancer Acti on NetworkSM 2 The American Cancer Society Cancer Action Network SM (ACS CAN) is making cancer—and the affordability of cancer care—a top priority for public of&# ND. , 2022. @anaeze_offodile. FINANCIAL TOXICITY & BREAST CANCER CARE. 17.8% of Americans report medical debt. JAMA 2021; 321(3): 250-56. Total medical debt in collections = $140 billion. Most people report significant medical debt. how . the pandemic has influenced the disease burden. Bengt . Jönsson. Professor emeritus, Stockholm School of Economics. Wednesday, 1 July 2020 – 16.30-19.00 CET (online event. ). Launch of the European Parliament  . South African NCD Alliance – grouping of Diabetes South Africa, Heart and Stroke Foundation, CANSA.. A community based NGO with a collective 160years of experience. Razana Allie (RN) Diabetes Nurse Specialist . Stays. Anyk Glussich. Program Lead, . Financial Standards and Information (FSI). Canadian Institute for Health . Information (CIHI). 2016 CADTH Symposium. April 12, 2016. 1. CIHI Mandate. To lead the . The current costs of the attendances which could have attended another model according to the analysis . 1. Model. : enhanced illness and assessment. Number of eligible patients . Eligible patients as a proportion of total (%).